Clinical Trial Update: Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trials evaluated the safety and efficacy of Deferasirox (ICL670) for iron overload caused by hereditary hemochromatosis, with results posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemochromatosis
• Iron Overload

Drugs mentioned

• Deferasirox (ICL670) (deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Iron Overload, Hereditary Hemochromatosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2011-05-18